Skip to main content

15-11-2018 | Pregnancy | Article

Successful Outcomes with Insulin Degludec in Pregnancy: A Case Series

Journal: Diabetes Therapy

Authors: Siwaporn Hiranput, S. Haris Ahmed, Deborah Macaulay, Shazli Azmi

Publisher: Springer Healthcare


Optimal glycaemic control pre-conception and throughout pregnancy is paramount to achieve the best outcomes and to minimise the risk of complications for the mother and baby. Current long-acting insulin analogues that have been approved by the National Institute for Health and Care Excellence in the UK for use in pregnancy include glargine and detemir. In many patients, these treatments have limitations because of their pharmacokinetic properties thus not enabling optimal glycaemic control. Efforts at rapidly achieving the recommended blood glucose targets with these analogues can be associated with recurrent and/or disabling hypoglycaemia. Degludec is a second-generation ultra-long-acting insulin analogue, which has been shown to mimic endogenous basal insulin production by the pancreas. This may offer patients better control with less hypoglycaemia where first-generation insulins fail. There are currently no randomised controlled studies to support the use of insulin degludec in pregnancy. We report three cases of women who were on insulin degludec during pregnancy and achieved successful outcomes. Two of them were commenced on this during pregnancy because of hypoglycaemia with licenced insulin therapy. All the women showed an improvement in glycaemic control during pregnancy. There was attenuation of a wide glycaemic variability as demonstrated by a continuous glucose monitoring (CGM) system in one of the patients. They all delivered healthy babies. This case series highlights the urgent need for large randomised control trials to establish the safety and efficacy of insulin degludec in pregnancy.
NICE. Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period. http://​www.​nice.​org.​uk/​guidance/​ng3. Accessed 22 Jun 2018.
Kalra S. Insulin degludec: a significant advancement in ultralong-acting Basal insulin. Diabetes Ther. 2013;4(2):167–73.CrossRef
Heise T, Nosek L, Bøttcher SG, et al. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14(10):944–50.CrossRef
Jovanovic L, Ilic S, Pettitt DJ. Metabolic and immunologic effects of insulin lispro in gestational diabetes. Diabetes Care. 1999;22(9):1422–7.CrossRef
Bhattacharyya A, Brown S, Hughes S, et al. Insulin lispro and regular insulin in pregnancy. QJM. 2001;94(5):255–60.CrossRef
Mathiesen ER, Kinsley B, Amiel SA, et al. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care. 2007;30(4):771–6.CrossRef
Negrato CA, Montenegro Junior RM, Von Kostrisch LM, et al. Insulin analogues in the treatment of diabetes in pregnancy. Arq Bras Endocrinol Metabol. 2012;56(7):405–14.CrossRef
Nasrallah SN, Reynolds LR. Insulin degludec, the new generation basal insulin or just another basal insulin? Clin Med Insights Endocrinol Diabetes. 2012;5:31–7.CrossRef
Russell-Jones D, Gall MA, Niemeyer M, et al. Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: a meta-analysis of seven clinical trials. Nutr Metab Cardiovasc Dis. 2015;25(10):898–905.CrossRef
Gough SC, Bhargava A, Jain R, et al. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care. 2013;36(9):2536–42.CrossRef
Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1498–507.CrossRef
Milluzzo A, Tumminia A, Scalisi NM, et al. Insulin degludec in the first trimester of pregnancy: report of two cases. J Diabetes Investig. 2018;9(3):629–31.CrossRef
Formoso G, Ginestra F, Di Dalmazi G, et al. Empagliflozin, metformin and insulin degludec, during pregnancy: a case report. Acta Diabetol. 2018;55(7):759–61.CrossRef
European Medicines Agency (EMA). London: Committee for Medicinal Products for Human Use, 2013. http://​www.​ema.​europa.​eu/​docs/​en_​GB/​document_​library/​EPAR_​-_​Product_​Information/​human/​002499/​WC500139011.​pdf. Accessed 17 Jun 2018.
Feig DS, Donovan LE, Corcoy R, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet. 2017;390(10110):2347–59.CrossRef
Martis R, Brown J, McAra-Couper J, et al. Enablers and barriers for women with gestational diabetes mellitus to achieve optimal glycaemic control—a qualitative study using the theoretical domains framework. BMC Pregnancy Childbirth. 2018;18:91.CrossRef

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »